

(12) **UK Patent Application** (19) **GB** (11) **2 235 292** (13) **A**
(43) Date of A publication 27.02.1991

(21) Application No 9016162.1

(22) Date of filing 24.07.1990

(30) Priority data

(31) 398621

(32) 25.08.1989

(33) US

(71) Applicant
ORD Corp

(Incorporated in the USA – New Hampshire)

334 North Main Street, North Salem,
New Hampshire 03073, United States of America

(72) Inventor
Myron J Block

(74) Agent and/or Address for Service

Potts Kerr & Co

P O Box 688, Ascot, Berkshire SL5 8YT,
United Kingdom

(51) INT CL⁶

G01N 33/58 33/543

(52) UK CL (Edition K)

G1B BAD B121 B306

(56) Documents cited

None

(58) Field of search

UK CL (Edition K) G1B BAD BAG

INT CL⁶ G01N 33/58

Online database: WPI, DIALOG/BIOTECH

(54) **Multiplex assay using distinguishably tagged ligands**


(57) The assay method comprises providing at least two different and distinguishably tagged ligands in a predetermined ratio, at least a first of said ligands being capable of specifically binding with the analyte, contacting the ligands and sample to form a body including a complex involving at least said first ligand and said analyte and contemporaneously quantitatively and separately measuring such of each of said tags as is coupled only to bound ligands in said body. If the relative non-specific binding characteristics of the ligands with respect to the assay apparatus are known, the binding of the first ligand to the analyte can be determined. When three differently tagged ligands are used, the first two may bind to different sites on the same analyte or to different analytes. The assay apparatus includes a reaction surface on which the first ligand(s) may be immobilised and which may be a surface of an attenuated total reflection cell.

At least one drawing originally filed was informal and the print reproduced here is taken from a later filed formal copy.

GB 2 235 292 A

CGK00032961

1/1



MULTIPLEX IMMUNOASSAY SYSTEM

This invention relates to chemical and biochemical assays involving one or more ligands that will specifically bind to respective reactive moieties of interest, and more particularly to multiplex assays of
5 that type.

Immune reactions involving the formation of antibody-antigen complexes are exemplary of known chemical or biochemical analyte/ligand reactions in which a complex is formed by the reaction of moieties
10 that will highly specifically bind to one another. A number of other such reactions are known, for example, nucleic acid hybridizations, enzyme-inhibitor, enzyme-coenzyme, hormone-receptor, enzyme-receptor and like substrate-specific reactions. The terms "moiety"
15 and "ligand" as used herein generally interchangeably refer to the reactive portions of such complex, and with respect to an antigen-antibody complex, for example, these terms are intended to include all immunologically reactive portions such as haptens,
20 complete antigens, reactive antigen-antibody fragments, and complete antibodies. The term "analyte" is intended to refer to the moiety or ligand being assayed either qualitatively, quantitatively or both, and the term "captor" is intended to refer to
25 the ligand or moiety that will specifically bind to the analyte of interest.

Assays based upon these well known immune and other specific binding reactions involve a wide variety of techniques. Some assay methods employ

radioactive, luminescent or fluorescent tags that are coupled to either the ligand or to the analyte, and can be detected by measuring radiation arising from the reaction product or complex. Typically, where a
5 captor such as an antibody immobilized on a substrate, is reacted in a solution containing an unknown quantity of a reactant moiety or analyte such as an antigen intended to bind to the captor, the titer of the antigen can be obtained easily. For example, in
10 the well-known competition assay technique a mixture of the analyte and a known amount of tagged analyte are applied to the immobilized phase and will compete with each other for the binding site. The greater the amount of the sample analyte present, the less will be
15 the extent to which tagged analyte will bind to the captor. Using predetermined calibration curves and measuring the intensity of the radiation from the tagged antigen complexed with the bound captor, one can determine or assay the amount of untagged or
20 sample analyte.

In another common technique, one may add the test solution containing analyte to a captor in solution. Assuming that the complex formed will aggregate sufficiently to precipitate or agglutinate,
25 observation of such resulting agglutination or precipitation reaction would indicate whether or not the test solution contained the analyte for which the captor is specific. In the latter case, the observation would be of radiation either reflected or
30 scattered from the agglutinate or precipitate, or radiation the transmission of which is attenuated by

the agglutinate or precipitate.

In immunoassays in which radiation (e.g., alpha radiation, luminescent radiation or fluorescent radiation) arises from the reaction product, one may
5 detect and/or measure the radiation typically with Geiger or scintillation counters, autoradiography, fluorimeters and the like.

It is postulated that the binding forces involved in antibody-antigen reactions are the combined
10 interaction of electrostatic, hydrogen bond and van de Waals forces, in many ways similar to other specific binding as, for example, that occurs in enzyme-substrate and in forming enzyme-coenzyme complexes, thereby providing a very strong, specific
15 bond. The specificity of such binding reactions is, however, not absolute. Because moieties, particularly labeled antibody, involved in such specific reactions can often bind to other materials, in assays such as immunoassays and captor assays that depend upon the
20 specificity of the binding, the occurrence of such non-specific binding can have adverse effects on the sensitivity and repeatability of the assay. It will be apparent that the term "bound" as used herein is thus intended to refer to ligands that are bound
25 through any type of binding, specific or non-specific.

Prior art attempts to overcome the effects of non-specific binding on assays have been primarily chemical and are directed to the use of reagents containing proteins that are intended to suppress or
30 block non-specific binding. Such reagents, however, are not universally effective, as reflected by the

fact that many different kinds of blockers (e.g., fetal calf serum, gelatin, casein, etc.) have been used in antibody-antigen assays.

In the discussion hereinafter, for the sake of convenience, assays involving specific binding reactions will be exemplified by reference to immunoassays, it being, however, understood that the principles involved, unless specifically noted, can apply to other types of assays involving specific binding reactions.

Achieving the ultimate sensitivity of measurement involving a specific binding reaction is not a matter of having the most powerful signal and the most sensitive instrumentation. Some sensitivity cannot be improved through improvements in the tag and instrument because of the limits imposed by antibody affinity.

For example, consider a capture or noncompetitive immunoassay. In principle, the latter has a potential for greater sensitivity than a competitive immunoassay because the effects of low antibody affinity can be overcome by an increase in the concentration of labelled antibody. The potential sensitivity advantage of a noncompetitive method over a competitive method, using the same antibody in each, increases with the decreasing affinity of the antibody. Using an antibody affinity of $10^{12}M$, if, for example, the effect of non-specific binding can be reduced from 1% to 0.01%, the potential assay sensitivity would go up from 10^5 to 10^3 molecules/ml. Increasing the amount of labelled antibody, however,

would be accompanied by an increase in the absolute amount of non-specific binding of the labelled antibody, reducing the ability to distinguish the smaller amounts of antigen, and may eliminate or
5 reduce the actual sensitivity advantage of a noncompetitive method.

In a conventional approach in ligand-bonding measurements, non-specific binding is usually estimated by first making a series of external
10 measurements (i.e., apart from or preliminary to the actual measurement of the binding) for the zero response of the instrument system being used, i.e., a measurement of non-specific binding outside of the assay to be performed, achieved by assay of a sample
15 known to contain none of the analyte of interest. In general, such measurements are not constant but fluctuate about some average value. From such series of measurements, one can define an average non-specific binding (NSB) response and an NSB noise
20 level where the root-mean-square (RMS) noise in the NSB measurements is equal to the standard deviation of the NSB responses. In subsequent assays of unknown analyte concentration, the specific response can then be taken as the system response minus the average NSB
25 response. Of course, in order to be certain that a given sample contains analyte, it is necessary that the specific response be greater than the noise. At very small analyte levels, the noise is usually dominated by the NSB noise.

30 Accordingly, a principal object of the present invention is to provide a ligand-bonding measurement

system that employs an "internal" reference that can be used to supplement "external" control measurements to improve the sensitivity of the system. Yet another important object of the present invention is to
5 provide such a system in which the effects of non-specific binding of labelled ligand such as antibody, are suppressed or minimized, thereby increasing the sensitivity of the assay beyond that presently achievable by prior art immunoassay systems.

10 Other objects of the present invention will in part be obvious and will in part appear hereinafter.

The invention accordingly comprises the apparatus possessing the construction, combination of elements and arrangement of parts, and the method comprising
15 the several steps and the relation of one or more of such steps with respect to each of the others, all of which are exemplified in the following detailed disclosure, and the scope of the application of which will be indicated in the claims.

20 For a fuller understanding of the nature and objects of the present invention, reference should be made to the following detailed description taken in connection with the accompanying drawing wherein there is shown an idealized, partly schematic, partly
25 cross-sectional view of apparatus embodying the principles of the present invention.

The system of the present invention generally comprises a multiplex assay system in which signals proportional to the extent of binding of two different
30 ligands in the system are made and evaluated in real time, typically contemporaneously, i.e., either

substantially simultaneously or in a sequence of observations or measurements taken within a comparatively short time with respect to the same sample under assay. It is preferred in most instances
5 to make the observations as nearly simultaneously as possible to reduce any effects of fast changes in background.

The multiplex system of the present invention should be distinguished from known multichannel assays
10 in which two or more analytes are substantially simultaneously assayed using different labelled ligands that will respectively uniquely specifically bind to the corresponding analytes. Cf. A Dual Radioimmunoassay for the Detection of Morphine and
15 Cocaine in Urine, A.S. Young, F. Rubio and S.E. Wagner, Clinical Chemistry, Vol. 34, No. 6, 1988, p. 1161.

A typical embodiment of the multiplex assay system of the present invention, however, is one that
20 determines the specific binding reaction with a specific analyte of interest in a sample, in which system two or more differently labelled ligands, each with its own different binding characteristics, are contemporaneously observed with respect to the sample
25 in the system. The responses obtained are processed to reduce the effects of non-specific binding in such assay, so that the specific binding response can be more accurately determined.

The method of the present invention, therefore,
30 provides for an assay for an analyte of interest in a sample. The method comprises the step of providing at

least two different ligands each coupled to a respective different type of tag distinguishable one from the other, at least a first of such ligands being capable of specifically binding with that analyte.

5 The ligands and the sample are contacted with one another, as by mixing, to form a test body (which may be a liquid volume) including a complex involving at least that first ligand and the analyte. Measurement is then made contemporaneously, quantitatively and
10 separately of such of each of the tags as are coupled only to bound ligands in the test body, and those measurements are compared. Measurements, of course, can be more easily made by first segregating the bound from the unbound ligands, as by washing the unbound
15 ligands away.

The present invention is embodied in apparatus for assaying for the analyte in the sample by specifically binding the analyte to an immobilized ligand on a reaction surface to form a complex. Specific binding
20 is effected by contacting the sample with the immobilized ligand and a different and differently tagged second ligand. The two different ligands are provided in predetermined proportion to one another, and are not immunologically cross-reactive.
25 Preferably the second ligand will not specifically bind to the analyte or to other moieties in the sample. The different tags on the ligands can be measured quantitatively. The relative non-specific binding characteristics of those ligands with respect
30 to the apparatus are in a known or predetermined function or relationship. Quantitative measurement of

those tags coupled only to bound quantities of the ligands is then made substantially contemporaneously. From the known proportion of ligands in the test body, the known relationship between the non-specific binding characteristics of the ligands to the apparatus, and the quantitative measurement of the bound tags, one can relatively accurately determine the specific binding of the first ligand to the analyte.

Particularly, the different tags are selected so that they can respectively provide signals that are readily distinguishable from one another, e.g., fluoresce at different wavelengths. Thus, the quantitative measurements made are of the amplitude of the signals provided from the excited tags that are coupled to those ligands which are both specifically and non-specifically bound in the course of the assay. Because the relative proportion of ligands to one another in the test body or reagent is known, and because also the relationship between the non-specific binding characteristics of those ligands with respect to the assay apparatus is also known or predetermined, it becomes relatively simple for one to then determine in real time, the extent to which the signals measured with respect to the only ligand that would specifically bind to the analyte are due to such specifically bound ligand.

For example, assume that the ligand (L_s) that will specifically bind to the analyte and the ligand (L_n) that will not specifically bind to the analyte are present in a ratio (R_1) of 1:1 in the test body in the

form of a reagent. Further assume that pretesting of the reagent in the assay apparatus in the absence of any of the analyte of interest has established that the ligands will bind non-specifically in the ratio
5 (R₂) of 1:2 (L_S:L_N). The assay then requires that the sample with the analyte of interest, if any, is contacted with the reagent body. This will result in both the specific binding of the analyte and L_S, and the non-specific binding of the ligands to the assay
10 apparatus (which term in this context should be understood to include any binding reactions that occur other than the specific binding of the analyte to L_S). Simultaneous measurement is then made of the distinctive and separate signals (i.e., separate
15 channel measurements) from the respective tags on the bound ligands. In an idealized case, the signals from L_N will be due only to ligand L_N that was non-specifically bound whereas the signals from L_S will arise from ligand that is both specifically and
20 non-specifically bound. Because it is known that the ligands were present in ratio R₁ and the relative non-specific binding characteristics of those ligands in the reagent was R₂, then one can employ these relationships to determine the extent of the signal
25 that arose from specifically bound L_S.

For example, assume that the amplitudes of the signals are measured at A_S and A_N, representing respectively the specifically and non-specifically bound L_S and the non-specifically bound L_N, then the
30 portion S of the signal A_S due only to the specifically bound L_S can be expressed as:

(1) $S = A_S - A_{nf}(R_1, R_2)$

where $f(R_1, R_2)$ is a function (not necessarily either linear or non-linear) of the values R_1 and R_2 .

A simple exemplary form of the function as a product is:

(2) $f = k_1 R_1 k_2 R_2$

where k_1 and k_2 are simply proportionality or weighting constants to be determined empirically.

A variation on the present invention is embodied in assay apparatus as described above, but one in which, additionally there is employed yet another or third ligand tagged with a tag that can be measured quantitatively, can be differentiated readily from the tags on the other two ligands, and will specifically bind to either a different site on the analyte of interest or to a different analyte. All three ligands are, of course, in a predetermined proportion to one another, the ligands being not immunologically cross-reactive. The relative non-specific binding characteristics of those three ligands with respect to the apparatus are in a known or predetermined function or relationship. This system then provides three channels, two specific and one non-specific, from which channels the specific binding characteristics of the two specifically-binding ligands can be determined.

One embodiment of the present invention can advantageously be described in a context of a fluorescent immunoassay system employing fluorescent tags, particularly an assay employing attenuated total reflection (ATR) cells, but it is to be understood

that the principles of the invention extend to other types of assays involving specific binding reactions and employing other types of detectable tags.

5 The use of an ATR cell in the form of a slab of radiation transmissive material, to observe and measure fluorescence induced at a cell surface by an evanescent wave and travelling across the cell substantially normal to the plane of that cell surface, was first suggested by T. Hirschfeld in U.S. Patent No. 3,604,927. A more sophisticated ATR
10 immunoassay apparatus is shown and described in detail in U.S. Patent No. 4,558,014 issued December 10, 1985 and the description of and operation of such an ATR cell is incorporated herein by reference. A distinct
15 advantage is obtained by using such an ATR cell in the present invention, because fluorescent signals detected by such a cell arise only within the evanescent zone adjacent the reaction surface of the cell. Thus, the cell, per se, automatically
20 segregates free ligands from those ligands that are non-specifically bound to the reaction surface and that are specifically bound in complexes formed at the reaction surface.

Referring to the drawing, there is shown a
25 cross-section of a fragment of totally internally reflecting assay cell 10. One preferred embodiment of cell 10 comprises a cylindrical rod or fiber 12 that is an elongated, substantially cylindrical, optically transparent body adapted to propagate along its length
30 by multiple total internal reflections, optical radiation entering an end of the fiber within an

established solid angle substantially rotationally symmetric about the longitudinal axis of the fiber. By way of example, fiber 12 may be any of a number of optically transparent materials such as glass, quartz, sapphire, polypropylene, polyolefins, nylon and the like, having an index of refraction greater than that of the fluid sample being assayed. As will be described hereinafter, a synthetic polymer is preferred inasmuch as the attachment thereto of a coating hereinafter described can be effected more readily than to an inorganic substrate such as glass. Preferably, fiber 12 is enclosed within capillary tube 14 formed of a material that is relatively insoluble and non-reactive with the fluid being assayed. Fiber 12 passes through and is supported coaxially within capillary tube 14 typically by stopper 16, thereby disposing all of the fiber except for end face 18 within tube 14.

Disposed on a portion of the outer surface of fiber 12 is an immobilized or prebound coating which, for example, can be formed of one of the reactants of an immune type reaction, i.e., a moiety of an antigen-antibody complex. Typically, coating may be applied by first providing the fiber surface or substrate with a plurality of coupling sites and then a number of the desired moieties of an antibody-antigen complex may be bound to those sites, preferably covalently and in known manner. The coupling sites on the substrate to which the selected moieties of the antigen-antibody complex are initially immobilized are selected so as to provide the

requisite immobilization without appreciably affecting the affinity and avidity of the moiety for the complementary portion of the complex. Where fiber 12 is glass, appropriate attachment sites may be provided
5 as is well known, for example, by reacting a silyl compound with the glass surface. Coupling of other suitable silyl compounds, and methods by which carboxyl, amino and other reactive groups of antibody or antigen may be covalently bound to various
10 inorganic materials are described by Weetall in U.S. Patent No. 3,652,761. Binding to polymers is often easier and there is extensive literature describing the immobilization of antibodies and antigens on the surface of polymers. Coating 24 may also be applied
15 by adsorption in some instances, by simply wetting the cell surface with a suitable reagent having an appropriately selected moiety.

For example, for the well known sandwich assay, the selected moiety to be immobilized on the ATR
20 substrate would be a ligand that will bind specifically to the analyte of interest. Such ligand is preferably provided in sufficient quantity to yield a number of reaction sites well in excess of the number of analyte molecules or moieties to be assayed,
25 so that the reaction sites will not be saturated subsequently. The coated cell would then be contacted with both the sample that may contain the analyte being assayed and the reagent containing the two labelled or tagged ligands, and the reactants allowed
30 to incubate for a time sufficient to insure that the binding reactions have been substantially completed.

Signals obtained from the tagged ligands that have bound to the immobilized analyte and have non-specifically bound to other portions of the assay apparatus are then measured. The signal measured from the second bound ligand (i.e., that which is not capable of specifically binding to the analyte) can then be used to predict (through a nomogram, table or formula) what amount or proportion of the signal received from the first bound ligand arose from the specific binding of the latter to the analyte.

In the ATR system described as exemplary, source 24 is provided for delivering beam 22 of light to cell 10. While source 24 can be a broadband source light such as a condenser illuminated with light from an incandescent lamp, a light-emitting diode, sunlight and the like, it is preferred that source 24 constitutes a dual source to provide excitation radiation within a pair of narrow wavelength bands, and to this end can include appropriate band pass filters. The center wavelengths of the two bands are chosen in accordance with the absorption characteristics of the fluorophors used as the tags on the labelled ligands, so as to excite the latter into fluorescence when illuminated. Light source 24 also includes appropriate beam shaping means, as understood by those skilled in the art, to illuminate objective lens 28 with a beam of appropriate vergence so as to permit lens 28 to image the source aperture on end face 18, preferably with no ray incident on face 18 at an angle greater than that corresponding to the numerical aperture of the fiber.

Means, such as beamsplitter 30, are interposed between source 24 and lens 28. In a preferred embodiment, beamsplitter 30 is formed so as to reflect the two excitation wavelength bands and transmit the
5 respective fluorescent emissions from face 18.

If the sample containing analyte is introduced into interspace 32 between fiber 12 and tube 14, the analyte will react with the immobilized ligand in coating 20 assuming that the ligand has been selected
10 to specifically bind to that analyte and some of the analyte is present in the sample. If now, to perform a sandwich assay, one introduces the two differently labelled different ligands into interspace 26, the first labelled ligand will specifically bind both to
15 free analyte and to analyte that had been bound to the immobilized ligand. The second labelled ligand will not specifically bind to the analyte, but can be expected to non-specifically bind to the surface of fiber 12 as some of the first labelled ligand will
20 also do.

Upon introducing a light beam from source 24 at an appropriate angle into face 18 of fiber 12, the beam will propagate through the fiber by total internal reflection, creating an evanescent wave in an
25 evanescent zone (not shown) contiguous with the fiber surface. The evanescent wave, where incident on such bound ligands will cause the labels or tags to fluoresce at two different wavelengths or in two different channels, and a large part of that
30 fluorescence will be directed or tunneled back into the medium of fiber 12, some at or above the critical

angle and some below the critical angle. Light directed back into the cell at or above the critical angle will be propagated through fiber 12, some emerging from input face 18.

5 Measurement of the respective amplitudes of the two different wavelengths of fluorescent light emergent from face 18 by electrooptical detection means 34 will indicate the respective quantitative presence of the bound ligands. To this end means 34
10 may comprise two electrooptical detectors respectively sensitive to the respective wavelengths. Alternatively, one may also employ, in lieu of source 24 and detection means 34, a fluorimeter having
15 switchable excitation and emission filters respectively appropriate to the excitation and detection of emission from the corresponding tags. Such measurements of the amplitudes of the signals from the tags, together with the other predetermined information regarding the values of R_1 and R_2 can then
20 be fed into means 36, such as an appropriately programmed digital computer or a properly hard-wired circuit, to make the desired determination, as described above, of the extent of the specific binding achieved.

25 The utility of a multiplex system for determination of non-specific binding in the presence of specific binding was shown in a test system exemplified in the following detailed example. The test reagent was formed of goat antbovine IgG (as the
30 first ligand expected to specifically bind to bovine IgG) labelled with fluorescein in known manner, and of

goat antimouse IgG (as the second ligand) labelled with rhodamine in known manner. The ATR cell, a polystyrene-coated quartz fiber, was coated, at least in a reaction zone on its surface, with bovine IgG.

5 These reagents were obtained from Jackson Immunological Corporation and the antibodies were prescreened by the supplier for cross-reactivity.

A preliminary determination of the non-specific binding of both antibodies was first made with respect
10 to a number of substantially identical bare, polystyrene-coated quartz fibers by first incubating the latter in phosphate-buffered saline (PBS) solution (pH 7.4) obtained from Sigma Chemical. After incubation, each of the fibers was placed in a flow
15 cell in an ATR fluorimeter having a pair of detector channels respectively responsive to the major wavelengths of fluorescein and rhodamine respectively (530 nm and 580 nm). A preferred embodiment employs a fluorimeter having switchable excitation and emission
20 filters respectively appropriate to the excitation and detection of fluorescence from fluorescein and rhodamine, i.e., excitation filters 480/20 (480 nm center wavelength, 20 nm bandpass) for fluorescein and 530/30 for rhodamine; fluorescence filters of 530/30
25 for fluorescein and 580/20 for rhodamine.

Each fiber was washed in flowing PBS for two minutes. Flow was stopped, excitation light (480 and 530 nm in sequence) of fixed intensity was introduced into the fiber at one end, and background readings (in
30 mV) were recorded for each of the two channels, one reading the background in the fluorescein detection

channel and one in the rhodamine detection channel. The PBS was then flushed from the flow cell and replaced with a flow of solution of equal volumes of 7.5 ug/ml rhodamine-labelled antimouse IgG and 7.0
5 ug/ml fluorescein-labelled antibovine IgG. Flow was stopped and the fiber allowed to incubate for two minutes at room temperature. The antibody solution was then washed out with a flow of PBS for four minutes. The same excitation light was again
10 introduced into the fiber and readings (in mV) representing the sum of the respective backgrounds and the non-specific binding were taken to obtain values of A_f and A_r for the fluorescein and rhodamine channels respectively for four such fibers.
15 The data are summarized in the following Table A in which A_f and A_r are respectively the amplitude in mv. of the signals received from the bound fluorescein and rhodamine-labelled IgG. Pre- and post-inc. refer to the signals measured respectively prior to
20 incubation and after incubation and wash. The binding response is simply the difference between the pre-inc. and post-inc. respective signals, and the binding ratio is the ratio of the binding responses.

TABLE A

<u>System Response</u>				<u>Binding Response</u>		<u>Binding Ratio</u>	
Pre-inc.		Post-inc.					
<u>A_f</u>	<u>A_r</u>	<u>A_f</u>	<u>A_r</u>	<u>A_f</u>	<u>A_r</u>	<u>Fluor/Rhod.</u>	
5	303	297	712	651	409	354	1.155
	398	492	1170	1080	772	588	1.313
	338	322	744	668	406	346	1.173
	397	355	8955	764	498	409	1.218

- Note that the average binding ratio was 1.215.
- 10 with a standard deviation of 0.070 and a C.V. of 5.798%. The average NSB response for A_f was 521 mv with a standard deviation of 172.5 mv (C.V. 33%), which in effect is a measure of the noise at zero analyte level.
- 15 The foregoing responses were, of course, made of surfaces that were bare of antigen. It will be appreciated, however, that one can make a similar series of measurements on a fiber blocked with a
- 20 specifically bound by either of the antibodies. Using such blockers should serve to reduce possible unwanted effects due to differences in the non-specific binding characteristics of the antibodies with regard to blocked and bare fibers respectively.
- 25 The same mixture of antibodies was then reacted with five of the identical fibers as previously used. The same procedure as described was followed except that the fibers were prepared by incubation for five minutes in 0.5 ug/ml bovine IgG rather than by
- 30 incubation in PBS. The results of the example are shown in Table B.

TABLE B

	<u>System Response</u>				<u>Binding Response</u>	
	<u>Pre-inc.</u>		<u>Post-inc.</u>		<u>A_f</u>	<u>A_r</u>
	<u>A_f</u>	<u>A_r</u>	<u>A_f</u>	<u>A_r</u>		
5	729	501	1650	1183	921	682
	568	435	1508	987	940	552
	478	457	1355	1030	877	573
	420	322	722	569	302	247
10	542	502	1530	1161	988	659

From this latter data it can be determined that the specific response provided by the fluorescein-labelled IgG was the total average A_f binding response minus 1.215 (the predetermined binding ratio found from Table A) times the average A_r . This yields an average binding response of 146.2 mv with a standard deviation of 102 mv.

The prior art conventional method of data analysis is to take the average A_f value from Table B and subtract from it the average A_f value due only to the non-specific binding as shown as the average A_f in Table A. Following this method, the average specific binding response is 284.6 mv and the standard deviation is 284.3 mv. A convenient method of comparison of the prior art and the method of the present invention is to determine the average signal-to-noise ratio (S/N) at the analyte level used. According to the prior art method then, the S/N is 284.6/284.3 or 1.00, where the method of the present invention gives a S/N of 146.2/102 or 1.43. This constitutes an improvement in S/N of about 1.5 at the

analyte level chosen and a reduction in the noise by a factor of about 2.8 in the zero analyte response.

Another example of multiplex apparatus of the present invention being used to determine NSB can be
5 seen from the following. It is known that a virus may elicit the formation of more than one type of antibody, e.g., two different antibodies respectively specific to the envelope and to the core of the virus. For diagnostic purposes, one may wish to assay a
10 sample, for example of blood, suspected of containing the antibodies to a specific type of such virus.

Consequently, one can immobilize lysate of that virus, for example, as a coating on the surface of an optical fiber, applied as by adsorption. That coated
15 fiber is then contacted with that sample, thereby forming complexes by specifically binding the lysate fragments of core and envelope with any respective corresponding antibodies that may be present in the sample. A reagent is prepared containing a known
20 ratio of first and second synthetic or natural proteins respectively corresponding to the envelope and core proteins of the virus and respectively labelled with fluorescent tags such as fluorescein and rhodamine in known manner. The reagent is mixed with
25 the sample and the coated fiber so that the proteins in that reagent can also specifically bind to those antibodies earlier bound to the lysate coating, and non-specifically bind elsewhere to the fiber.

The specific binding ratio of the two proteins is
30 determined by the ratio of the binding sites provided by the relative amounts of two antibodies present in

the sample and bound to the coating. If there is a
priori knowledge of the ratio of such binding sites,
then the reagent is prepared with a ratio of proteins
that is markedly different than the ratio of binding
5 sites.

The labelled proteins bound to the fiber are now
separately and substantially simultaneously excited
into fluorescence in the apparatus of the present
invention, providing signals produced by a combination
10 of specific and non-specific binding of the tagged
proteins. It will be apparent, however, that the
ratio of the respective signals produced by the tags
on proteins that are specifically bound corresponds to
the ratio of the binding sites, but the ratio of the
15 signals produced by tagged proteins that are
non-specific bound will correspond to the known ratio
at which the respective proteins are supplied in the
reagent. Where the ratio of binding sites or
antibodies is also known then, because the two ratios
20 differ considerably (being under the control of the
preparer of the reagent), the amplitudes of the
respective signals can be correspondingly adjusted to
remove the effect of the non-specific binding.

If there is no a priori knowledge of the ratio of
25 binding sites, i.e., the ratio of antibodies, one can
perform a preliminary assay using another reagent in
which the proteins are present in a first ratio, e.g.,
unity. Using the results of that assay, a second
assay is then performed with a second reagent in which
30 the ratio of proteins has been established, for
example, as the inverse of the measurement of the

signals in the first assay. The measurement of signals in the second assay supplies sufficient information from which one can make calculations that will separate out the effects of non-specific binding.

5 Since certain changes may be made in the above method and apparatus without departing from the scope of the invention involved, it is intended that all matter contained in the above description or shown in the accompanying drawing shall be interpreted as
10 illustrative and not in a limiting sense.

CLAIMS

1 1. Method for assaying for an analyte of interest
2 in a sample, said method comprising the steps of:
3 providing at least two different ligands each
4 coupled to a respective different type of tag
5 distinguishable one from the other, at least a first
6 of said ligands being capable of specifically binding
7 with said analyte;
8 contacting said ligands and said sample to form a
9 body including a complex involving at least said first
10 ligand and said analyte;
11 contemporaneously quantitatively and separately
12 measuring such of each of said tags as is coupled only
13 to bound ligands in said body; and
14 comparing the measurements of said tags.

1 2. Method as defined in claim 1 including the
2 steps of:
3 providing apparatus in which said assay is to be
4 conducted;
5 providing the two differently tagged different
6 ligands in a predetermined proportion to one another,
7 each of said ligands having different specific binding
8 characteristics with respect to said analyte of
9 interest, the non-specific binding characteristics of
10 said ligands with respect to said apparatus being in a
11 known correlation to one another;
12 contacting said ligands with said sample in said
13 apparatus so as to effect said specific binding and
14 form said complex; and

MJB-45

15 determining the specific binding of said first-
16 ligand with respect to said analyte from the
17 comparison of said measurements, said known proportion
18 and said known correlation.

1 3. Method as defined in claim 2 including the
2 step of segregating, after said contacting step,
3 substantially all of said analyte and ligands from
4 those ligands which are bound to said analyte and said
5 apparatus.

1 4. Method as defined in claim 3 wherein each of
2 said different tags, when excited, can respectively
3 provide signals distinguishable from one another, and
4 said measurements are of the amplitude of said signals
5 from substantially only the bound ligands.

1 5. Method as defined in claim 4 wherein each of
2 said different tags, when excited, provides
3 fluorescent radiation at wavelengths that differ from
4 one another.

1 6. Method as defined in claim 2 in which the
2 second of said ligands will not specifically bind to
3 said analyte or to other moieties in said sample.

1 7. Method as defined in claim 6 wherein said
2 first ligand is provided in excess of the amount
3 expected to specifically bind with said analyte in
4 said sample.

1 8. Method as defined in claim 4 including the-
2 step of determining said known correlation by:
3 preliminarily assaying said ligands in said
4 apparatus in the absence of said analyte so as to
5 quantitatively measure the amplitudes of the
6 respective signals from said tagged ligands that
7 become non-specifically bound during the preliminary
8 assay; and
9 determining the ratio of the measured signal -
10 amplitudes from said first ligand and the second of
11 said ligands.

1 9. Method as defined in claim 4 wherein said step
2 of determining is carried out by modifying, in
3 accordance with a function of said known proportion
4 and said known ratio, the value of the signal from the
5 second of said ligands to thereby provide a modified
6 value, and comparing to said modified value the
7 amplitude of the signal from said first ligand.

1 10. Method as defined in claim 4 wherein said
2 step of determining is carried out by subtracting from
3 the amplitude of the signal from said first ligand,
4 the product of said known ratio times said known
5 proportion times the amplitude of the signal from the
6 second of said ligands.

- 1 11. Apparatus for assaying a solution for an -
2 analyte of interest, said apparatus comprising, in
3 combination:
4 at least two differently tagged ligands each
5 labelled differently with respective tags, the
6 presence of which tags can be quantitatively
7 determined, at least a first of said ligands being
8 capable of specifically binding to said analyte;
9 a reaction surface at which at least said first
10 ligand can form a specifically-bound complex with said
11 analyte; and
12 means for contemporaneously quantitatively and
13 separately measuring such of each of said tags as may
14 be bound at said surface.
- 1 12. Apparatus as defined in claim 11 wherein said
2 first ligand is immobilized on said reaction surface.
- 1 13. Apparatus as defined in claim 11 wherein said
2 reaction surface is a surface of an attenuated total
3 reflection cell.
- 1 14. Apparatus as defined in claim 13 including
2 means for introducing radiation into said cell at
3 wavelengths capable of exciting both of said tags into
4 emitting respective different signals.

1 15. Apparatus as defined in claim 14 wherein said
2 means for contemporaneously quantitatively and
3 separately measuring comprises a pair of detectors
4 each respectively sensitive to one of said respective
5 different signals.

1 16. Apparatus as defined in claim 14 wherein said
2 means for contemporaneously quantitatively and
3 separately measuring comprises a fluorimeter having
4 switchable excitation and emission filters
5 respectively appropriate to the excitation and
6 detection of emission from said tags.

1 17. Method for assaying for an analyte of interest in a
2 sample substantially as herein described.

1 18. Apparatus for assaying a solution for an analyte of
2 interest constructed and arranged to operate substantially as
3 herein described with reference to and as illustrated in the
4 accompanying drawing.

MJB-45